CHRISTIE BALLANTYNE to Aspirin
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Aspirin.
Connection Strength
0.561
-
Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Netw Open. 2020 08 03; 3(8):e2011051.
Score: 0.149
-
Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry. J Am Coll Cardiol. 2015 Jan 20; 65(2):111-21.
Score: 0.101
-
Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. J Vasc Surg. 2011 Mar; 53(3):668-75.
Score: 0.077
-
Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost. 2009 Jul; 102(1):179-80.
Score: 0.069
-
Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J. 2008 Nov; 156(5):1002.e1-1002.e7.
Score: 0.066
-
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovasc Drugs Ther. 2021 06; 35(3):533-538.
Score: 0.037
-
Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. J Am Heart Assoc. 2018 06 09; 7(12).
Score: 0.032
-
Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. J Am Heart Assoc. 2017 Aug 03; 6(8).
Score: 0.030